Park SR - Search Results

1

Integrative modeling of tumor genomes and epigenomes for enhanced cancer diagnosis by cell-free DNA.

Bae M, Kim G, Lee TR, Ahn JM, Park H, Park SR, Song KB, Jun E, Oh D, Lee JW, Park YS, Song KW, Byeon JS, Kim BH, Sohn JH, Kim MH, Kim GM, Chie EK, Kang HC, Kong SY, Woo SM, Lee JE, Ryu JM, Lee J, Kim D, Ki CS, Cho EH, Choi JK. Bae M, et al. Among authors: park sr, park ys, park h. Nat Commun. 2023 Apr 10;14(1):2017. doi: 10.1038/s41467-023-37768-3. Nat Commun. 2023. PMID: 37037826 Free PMC article.

2

Association of CYP2A6 polymorphisms with S-1 plus docetaxel therapy outcomes in metastatic gastric cancer.

Kong SY, Lim HS, Nam BH, Kook MC, Kim YW, Ryu KW, Lee JH, Choi IJ, Lee JS, Park YI, Kim NK, Park SR. Kong SY, et al. Among authors: park yi, park sr. Pharmacogenomics. 2009 Jul;10(7):1147-55. doi: 10.2217/pgs.09.48. Pharmacogenomics. 2009. PMID: 19604090 Clinical Trial.

3

Cytotoxic effects of novel phytosphingosine derivatives, including N,N-dimethylphytosphingosine and N-monomethylphytosphingosine, in human leukemia cell line HL60.

Park SR, Cho HJ, Moon KJ, Chun KH, Kong SY, Yoon SS, Lee JS, Park S. Park SR, et al. Among authors: park s. Leuk Lymphoma. 2010 Jan;51(1):132-45. doi: 10.3109/10428190903383419. Leuk Lymphoma. 2010. PMID: 20001229

4

Phase I clinical and pharmacokinetic/pharmacogenetic study of a triplet regimen of S-1/irinotecan/oxaliplatin in patients with metastatic colorectal or gastric cancer.

Park SR, Hong YS, Lim HS, Seong MW, Kong SY, Kim SY, Park YI, Jung KH. Park SR, et al. Among authors: park yi. Cancer Chemother Pharmacol. 2013 Nov;72(5):953-64. doi: 10.1007/s00280-013-2272-0. Epub 2013 Aug 28. Cancer Chemother Pharmacol. 2013. PMID: 23982118 Clinical Trial.

5

A phase II study of perioperative S-1 combined with weekly docetaxel in patients with locally advanced gastric carcinoma: clinical outcomes and clinicopathological and pharmacogenetic predictors for survival.

Kim YW, Kim MJ, Ryu KW, Lim HS, Lee JH, Kong SY, Lee JS, Choi IJ, Kim CG, Lee JY, Cho SJ, Kook MC, Park YI, Kim SK, Park SR. Kim YW, et al. Among authors: park yi, park sr. Gastric Cancer. 2016 Apr;19(2):586-596. doi: 10.1007/s10120-015-0490-3. Epub 2015 Apr 8. Gastric Cancer. 2016. PMID: 25851942 Clinical Trial.

6

Associations between CYP2A6 polymorphisms and outcomes of adjuvant S-1 chemotherapy in patients with curatively resected gastric cancer.

Jeong JH, Park SR, Ahn Y, Ryu MH, Ryoo BY, Kong SY, Yook JH, Yoo MW, Kim BS, Kim BS, Kang YK. Jeong JH, et al. Among authors: park sr. Gastric Cancer. 2017 Jan;20(1):146-155. doi: 10.1007/s10120-015-0586-9. Epub 2015 Dec 29. Gastric Cancer. 2017. PMID: 26715117

7

A randomised phase II study of continuous versus stop-and-go S-1 plus oxaliplatin following disease stabilisation in first-line chemotherapy in patients with metastatic gastric cancer.

Park SR, Kim MJ, Nam BH, Kim CG, Lee JY, Cho SJ, Kong SY, Park YI. Park SR, et al. Among authors: park yi. Eur J Cancer. 2017 Sep;83:32-42. doi: 10.1016/j.ejca.2017.06.008. Epub 2017 Jul 14. Eur J Cancer. 2017. PMID: 28711577 Clinical Trial.

8

A randomized phase II study of S-1 versus capecitabine as first-line chemotherapy in elderly metastatic gastric cancer patients with or without poor performance status: clinical and pharmacogenetic results.

Kim MJ, Kong SY, Nam BH, Kim S, Park YI, Park SR. Kim MJ, et al. Among authors: park yi, park sr. Pharmacogenet Genomics. 2018 Jan;28(1):23-30. doi: 10.1097/FPC.0000000000000320. Pharmacogenet Genomics. 2018. PMID: 29189588 Clinical Trial.

9

Genome-wide copy number alteration and VEGFA amplification of circulating cell-free DNA as a biomarker in advanced hepatocellular carcinoma patients treated with Sorafenib.

Oh CR, Kong SY, Im HS, Kim HJ, Kim MK, Yoon KA, Cho EH, Jang JH, Lee J, Kang J, Park SR, Ryoo BY. Oh CR, et al. Among authors: park sr. BMC Cancer. 2019 Apr 1;19(1):292. doi: 10.1186/s12885-019-5483-x. BMC Cancer. 2019. PMID: 30935424 Free PMC article.

10

Genome-wide and size-based cell-free DNA indices as predictive biomarkers for locally advanced esophageal squamous cell carcinoma treated with preoperative or definitive chemoradiotherapy.

Kim EJ, Im HS, Lee J, Cho EH, Kim YH, Kim HR, Kim JH, Park SR. Kim EJ, et al. Among authors: park sr. Curr Probl Cancer. 2021 Jun;45(3):100685. doi: 10.1016/j.currproblcancer.2020.100685. Epub 2020 Nov 28. Curr Probl Cancer. 2021. PMID: 33342577

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

698 results

Search Page